BMY Q2 2021 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena

BMYBristol-Myers Squibb Company

$124B

Q2 2021 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$11.7B+15.5% YoY

Gross Profit

$6.7B57.3% margin

Operating Income

$1.6B13.3% margin

Net Income

$1.1B9.0% margin

EPS (Diluted)

$0.47

QoQ Revenue Growth

+5.7%

Cash Flow

Operating Cash Flow

$3.1B

Free Cash Flow

$2.9B

Stock-Based Comp.

$157M

Balance Sheet

Total Assets

$110.8B

Total Liabilities

$73.9B

Stockholders' Equity

$36.8B

Cash & Equivalents

$11.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11.7B	$10.1B	+15.5%
Gross Profit	$6.7B	$5.0B	+32.9%
Operating Income	$1.6B	$939M	+65.9%
Net Income	$1.1B	-$85M	+1341.2%

Revenue Segments

Revlimid

$3.2B28%

Eliquis

$2.8B24%

Opdivo

$1.9B17%

Pomalyst/Imnovid

$854M7%

Orencia

$814M7%

Sprycel

$541M5%

Yervoy

$510M4%

Mature Products And All Other

$319M3%

Abraxane

$296M3%

Reblozyl

$128M1%

Zeposia

$28M0%

Abecma

$24M0%

Breyanzi

$17M0%

Geographic Segments

UNITED STATES

$7.4B63%

Europe

$2.7B23%

Rest Of World

$1.4B12%

Other Region

$191M2%